← Eichor
Condition: Unresectable Non Small Cell Lung Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07609121A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2/Phase 3 · 11 location(s) · Swiss Cancer Institute · NCT07149649Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Phase N/A · 22 location(s) · Fundación GECP · NCT06634199A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
Phase 2 · 1 location(s) · Zhejiang University · NCT05837052A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Phase 2 · 20 location(s) · Fundación GECP · NCT05398094A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Phase 4 · 1 location(s) · Idris Bahce · NCT06908070RGL-270 + ICI in Advanced NSCLC
NA · 1 location(s) · Guangdong Association of Clinical Trials · NCT07652125A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresec
Phase 3 · 256 location(s) · Bristol-Myers Squibb · NCT07361497A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants Wi
Phase 3 · 264 location(s) · AstraZeneca · NCT05211895A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Pos
Phase 2 · 34 location(s) · RemeGen Co., Ltd. · NCT06962865A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mut
Phase 3 · 5 location(s) · Astellas Pharma Global Development, Inc. · NCT07566052Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Local
Phase 1/Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07632365A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT05940532A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lu
Phase 2 · 43 location(s) · Johnson & Johnson Enterprise Innovation Inc. · NCT06667908Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210PALACE: Cemiplimab Trial According to ctDNA Levels
Phase 2 · 20 location(s) · Fundación GECP · NCT06917573Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Phase 1/Phase 2 · 2 location(s) · Dana-Farber Cancer Institute · NCT04789486A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Astellas Pharma Global Development, Inc. · NCT07287995Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stag
Phase 2 · 25 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06656598Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · University of California, Davis · NCT07250477
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.